Drugs - December 2017

  • US: Mepergan Fortis Capsules; Final Decision on Proposal to Refuse Approval of Supplemental New Drug Application; Availability of Final Decision

  • US: Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products

  • US: Medicare Program; CY 2018 Updates to the Quality Payment Program; and Quality Payment Program: Extreme and Uncontrollable Circumstance Policy for the Transition Year

  • US: Medicare Shared Savings Program Requirements; and Medicare Diabetes Prevention Program for CY 2018

  • US: Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule

  • US: Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical

Center Payment Systems and Quality Reporting Programs

  • US: Unique Device Identification; Direct Marking of Devices

  • US: Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled

Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine and Phenylpropanolamine for 2017

  • US: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment

Parameters for 2019

  • US: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for

Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, and End-Stage Renal

Disease Quality Incentive Program

  • EU: UPDATE - Guidance published by Member States on the implementation of the Falsified Medicines Directive

Contact us at info@arq-on.com.

Recent Posts

See All

Europe - May 2020

Denmark: New rules mean non-serious adverse events may also need to be reported EU: Application of Regulation (EU) 2017/745 postponed by one year EU: Continued use of lead as a thermal stabiliser in P

EU: MDR delayed to 26 May 2021

Application of the Medical Devices Regulation (MDR) has been deferred by one year, until 26 May 2021, for fear of shortage or delay in getting essential medical devices needed to combat Covid-19. The

  • LinkedIn - White Circle
  • YouTube - White Circle
  • Twitter - White Circle
  • LinkedIn - White Circle
  • YouTube - White Circle
  • Twitter - White Circle



Call us:

   : +65 6909 0396

   : +65 9067 1432


Email us: info@arqon.com


© 2020 ARQon All Rights Reserved. 

  • LinkedIn - White Circle
  • YouTube - White Circle
  • Twitter - White Circle